|
| |
Cytopia LimitedCytopia aims to identify new candidate therapeutics (drug leads) for asthma and a range of inflammatory diseases. Many current drugs have significant side effects such as gastric upsets and ulcers and Cytopia's technology has the potential to discover more specific drugs without these side effects.
Cytopia has an exclusive, worldwide royalty-free license to commercially exploit technology developed by its Research Director, Dr Andrew Wilks, whilst at the Ludwig Institute for Cancer Research in Melbourne.
Licensed patents give Cytopia sole right to commercially exploit several genes and protein (known as JAK kinases) which play a crucial role in controlling the inflammatory process, for example in rheumatoid arthritis.
Cytopia is developing technology which allows large chemical collections to be tested for their ability to inhibit the activity of the patented proteins. Chemicals which are specifically active may be able to prevent certain inflammatory diseases.
| Contact Details: |
| 41, Victoria Parade |
| Fitzroy |
| Victoria |
| 3065 |
| Australia |
| Tel: | (613) 9288 2973 |
| Fax: | 613 9288 2013 |
| Email: | cytopia@cytopia.com.au |
| WWW: | www.cytopia.com.au/
|
| |
Recent Publications by Cytopia Limited: |  |
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.
CYT997 is a wholly synthetic compound that possesses highly potent... | 6th November, 2009
| Cytopia Research Pty Ltd, Richmond, Victoria, Australia.
| Mol Cancer Ther. 2009 Nov;8(11):3036-45. Epub 2009 Nov 3.
DOI Direct Link |
Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
CYT997 was discovered as a potent tubulin polymerization inhibitor... | 14th October, 2009
| Cytopia Research Pty Ltd, Richmond, VIC 3121, Australia.
| Bioorg Med Chem Lett. 2009 Aug 15;19(16):4639-42. Epub 2009 Jun 25.
DOI Direct Link |
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
A series of phenylaminopyrimidines has been identified as inhibitors of... | 19th September, 2009
| Cytopia Research Pty Ltd, 576 Swan St, Richmond, VIC 3121, Australia.
| Bioorg Med Chem Lett. 2009 Oct 15;19(20):5887-92. Epub 2009 Aug 23.
DOI Direct Link |
Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
A series of 2-(alpha-methylbenzylamino) pyrazines have shown to be potent... | 11th March, 2009
| Cytopia Research Pty Ltd, 576 Swan Street, Richmond, VIC. 3121, Australia.
| Bioorg Med Chem Lett. 2009 Feb 15;19(4):1206-9. Epub 2008 Dec 25.
DOI Direct Link |
Press Releases on Cytopia Limited:
|
 |
| YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING |
17th November, 2009 |
YM BioSciences Inc. |
MISSISSAUGA, ON, Nov. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of
|
| Cytopia Letter to Progen Shareholders |
25th February, 2009 |
Cytopia Limited |
MELBOURNE, Australia, Feb. 25 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has today circulated a letter and other materials to Progen Pharmaceuticals Limited (ASX: PGL) shareholders. The letter
|
| Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 |
5th February, 2009 |
Cytopia Limited |
MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular
|
| Cytopia Scientific Presentations on JAK2 Inhibitor Program |
16th October, 2008 |
Cytopia Limited |
MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present data on its JAK2 inhibitor program at two important scientific meetings this month.
Dr Emmanuelle Fantino, Head
|
| Cytopia Commences Second Phase II Study in Brain Cancer |
4th September, 2008 |
Cytopia Limited |
MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited (ASX: CYT)
today announced that it is commencing enrolment for its Phase Ib/II study of
CYT997, the company's novel vascular
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 372 times since April 2007, the link to the organisation's website has been followed 55 times Search for more companies in Fitzroy Search for more companies in Victoria This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cytopia Limited |
